Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Trump Orders Blockade of Sanctioned Oil Tankers, Raising Venezuela Tensions and Oil Prices
Yen Near Lows as Markets Await Bank of Japan Rate Decision, Euro Slips After ECB Signals Caution
Canada Signals Delay in US Tariff Deal as Talks Shift to USMCA Review
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
U.S. Dollar Steadies Near October Lows as Rate Cut Expectations Keep Markets on Edge
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Asian Fund Managers Turn More Optimistic on Growth but Curb Equity Return Expectations: BofA Survey
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data
Precious Metals Rally as Silver and Platinum Outperform on Rate Cut Bets
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
BoE Set to Cut Rates as UK Inflation Slows, but Further Easing Likely Limited
Asian Stocks Edge Higher as Tech Recovers, U.S. Economic Uncertainty Caps Gains
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 



